Documento
·
Da
Edoardo Di Matteo
Alle
30 gen 26, 14:57
Anno di
riferimento
del
Pagamento
Trimestre
Categoria di
spesa
Tipologia di spesa Importo Beneficiario
2025 IV uscite correnti Acquisto di beni e di servizi 489,00...
Documento
·
Da
Edoardo Di Matteo
Alle
24 lug 25, 16:06
Anno di
riferimento
del
Pagamento
Trimestre
Categoria
di spesa
Tipologia di spesa Importo Beneficiario
2025 2
Uscite
c/capitale
Investimenti in beni
materiali 59.780,00...
Documento
·
Da
Stefano Pesarin
Alle
17 ott 25, 10:38
Anno di
riferimento
del
Pagamento
Trimestre
Categoria
di spesa
Tipologia di spesa Importo Beneficiario
2025 3
uscite
correnti
Contributi in conto
esercizio 9.116.104,25
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
IATRIS contribution to
product development
Discovery Pre-Clin Phase I Phase II
IATRIS
Target
Valid.
Validation
in vivo
GMP
Synthesis
& Optimiz.
ToxicologyScreening Phase IIaPhase I
...
